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Abstract
DNA vaccines expressing the envelope (Env) of the human immunodeficiency virus type 1 (HIV-1)
have been relatively ineffective at generating high-titer, long-lasting, neutralizing antibodies. In this
study, DNA vaccines were constructed to express the gp120 subunit of Env from the isolate
HIV-1R2 using both wild-type and codon-optimized gene sequences. Three copies of the murine C3d
were added to the carboxyl terminus to enhance the immunogenicity of the expressed fusion protein.
Mice (BALB/c) vaccinated with DNA plasmid expressing the gp120R2 using codon-optimized Env
sequences elicited high-titer anti-Env antibodies regardless of conjugation to C3d. In contrast, only
mice vaccinated with DNA using wild-type gp120R2 sequences fused to mC3d3, had detectable anti-
Env antibodies. Interestingly, mice vaccinated with DNA expressing gp120R2 from codon-optimized
sequences elicited antibodies that neutralized both homologous and heterologous HIV-1 isolates. To
determine if the unique sequence found in the crown of the V3 loop of the EnvR2 was responsible
for the elicitation of the cross-clade neutralizing antibodies, the codons encoding for the Pro-Met
(amino acids 313–314) were introduced into the sequences encoding the gp120ADA (R5) or
gp12089.6 (R5X4). Mice vaccinated with gp120ADA–mC3d3–DNA with the Pro–Met mutation had
antibodies that neutralized HIV-1 infection, but not the gp12089.6–mC3d3–DNA. Therefore, the use
of the unique sequences in the EnvR2 introduced into an R5 tropic envelope, in conjunction with C3d
fusion, was effective at broadening the number of viruses that could be neutralized. However, the
introduction of this same sequence into an R5X4-tropic envelope was ineffective in eliciting
improved cross-clade neutralizing antibodies.
INTRODUCTION
At the end of 2003, approximately 42 million people were infected and living with the human
immunodeficiency virus type 1 (HIV-1), the pathogen associated with the onset of acquired
immunodeficiency syndrome (AIDS).1 Greater than 95% of new HIV infections occurred in
developing countries (70% men, 30% women). AIDS is a state of immunodeficiency that
weakens a patient's immune system resulting in the development of fatal opportunistic
infections. Despite the effectiveness of highly active antiretroviral therapy (HAART), there
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are several drawbacks that prevent its worldwide use, particularly for individuals in developing
nations.2–4 Therefore, one of the long-term goals of HIV/AIDS research has been the
development of a safe and effective vaccine.
The induction of highly cross-reactive neutralizing antibodies is one of the goals of HIV vaccine
development. A variety of vaccine strategies using envelope immunogens has failed to induce
antibodies capable of neutralizing cross-clade, primary isolates.5–7 The elicitation of
antibodies directed against Env appears to be a critical component of an AIDS vaccine.8 Cross-
reactive antibodies that neutralize primary isolates have been infrequently described in sera
from donors infected with HIV-1. However, reference serum prepared from a donor infected
in the United States with a clade B strain of HIV-1 has neutralizing antibodies that cross-react
extensively with primary HIV-1 isolates of various clades.9–11 The donor (HNS2) had a long-
term nonprogressive HIV-1 infection for more than 10 years.12 Relatively cross-reactive
antibodies that neutralize primary isolates have been described in sera from other donors with
long-term nonprogressive HIV-1 infections.13
The EnvR2, expressed from one of the env genes cloned from patient HNS2, can be neutralized
by sera from patients infected with HIV-1 from clades A, B, C, D, and F, as well as circulating
recombinant forms (CRF).12 Virions pseudotyped with the EnvR2 can mediate CD4-
independent infection. In addition, these viruses are sensitive to neutralization by a panel of
monoclonal antibodies that recognizes conformation epitopes in envelope.14 A rare mutation
found in the crown of the V3 loop, a proline (P) and methionine (M) (nucleotide position
313/314), appears responsible for the uncommon neutralization sensitivity phenotype and the
capacity of this envelope to mediate CD4-independent infection.14 Recently, Dong et al.15
expressed the EnvR2 from a Venezuelan equine encephalitis (VEE) replicon and elicited high
titer neutralizing antibodies in mice and rabbits following immunization. These properties are
consistent with the possibility that the EnvR2 expresses one or more neutralization epitopes
that are responsible for induction of cross-reactive neutralizing antibodies in the donor of
HNS2.
DNA vaccination (genetic vaccination) induces protective immunity against a variety of
pathogens.16–19 These genetic vaccines consist of eukaryotic expression plasmids that are
inoculated into target cells in the skin, muscle, or mucosal surfaces of a host and are translated
into proteins.7,20 DNA vaccination effectively induces both humoral and cellular immune
responses to immunogens from diverse infectious agents.5,17–19,21–23 The use of a variety
of HIV envelope immunogens has failed to induce antibodies capable of neutralizing more
than a fraction of primary isolates.5,7 Unlike most immunogens, multiple DNA immunizations
are required to elicit even modest titers of neutralizing antibody to the HIV envelope
glycoprotein.17,18,22,24–30 However, the elicitation of neutralizing antibodies appears to be
a critical component of any HIV vaccine.20,31
One approach advanced in our laboratory to enhance the immunogenicity to HIV-1 Env is the
use of the complement protein, C3d, as a molecular adjuvant. Conjugation of multiple copies
of C3d to an antigen enhances the immunogenicity of low or nonimmunogenic antigens.27,
32 C3d, when fused to an antigen, but not when coinoculated, enhances the total IgG titer
against the conjugated protein.27,32 Antibodies directed against (1) the hemagglutinin of
influenza or measles virus,22,33,34 (2) the merozoite surface antigen, MSP1.19, of
Plasmodium yoelii,35 (3) the capsular polysaccharide of serotype 14 Streptococcus
pneumonia,36,37 (4) the hepatatis B surface antigen (L. Wang, personal communication) were
increased between 1 and 3 logs following immunization with DNA-expressing C3d-conjugated
antigens. The addition of three copies of murine or human C3d to soluble forms of HIV-1
envelope accelerated both the onset and the avidity maturation of antibody in vaccinated mice
and enhanced neutralizing antibody titers compared to mice vaccinated with antigen alone.
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24,26,29,30 In addition, titers of neutralizing antibodies to influenza or measles viruses were
increased using DNA plasmids expressing C3d-fused hemagglutinin.21,33,34 Interestingly,
the precise mechanism of C3d enhancement is unclear, however, C3d appears to enhance
antibody and cellular responses via both CR2-dependent and -independent mechanisms.38
Therefore, the goal of this study was to analyze the effectiveness of the unique V3 sequence
from EnvR2 introduction into the env genes from two prototype R5 strains to determine if the
Pro–Met mutation would confer increased neutralization capacity following DNA vaccination.
These envelopes were expressed from either wild-type or synthetic codon-optimized sequences
alone or in conjunction with mC3d3 and then analyzed for both total IgG and neutralization.
MATERIALS AND METHODS
Plasmid vector DNA
pTR600, a eukaryotic expression vector, has been described previously.24,26,30,33,39 Briefly,
the vector was constructed to contain the cytomegalovirus immediate-early promoter (CMVIE)
plus intron A (IA) for initiating transcription of eukaryotic inserts and the bovine growth
hormone polyadenylation signal [BGH poly(A)] for termination of transcription. The vector
contains the ColE1 origin of replication for prokaryotic replication and the kanamycin
resistance gene (Kanr) for selection in antibiotic media.
Construction of DNA vaccines
Previously, gp120ADA and gp12089.6 expression plasmids and gp120ADA–C3d3 and
gp12089.6–C3d3 flusion constructs using wild-type Env gene sequences have been
characterized.26,29,30 Briefly, the envelope sequences from the isolate, HIV-1R2, encoding
almost the entire gp120 region were cloned into the pTR600 vaccine vector using unique
restriction endonuclease sites (Fig. 1A). C3d sequences were cloned in frame at the 3? end of
the gp120 gene. The first 32 amino acids were deleted from the N-terminus of each sgp120
and replaced with a leader sequence from the trypsin plasminogen activator (tpA). The vectors
expressing sgp120–mC3d3 fusion proteins were generated by cloning three tandem repeats of
the mouse homologue of C3d in frame with the sgp120-expressing DNA. The construct design
was based upon Dempsey et al.32 with glycine/serine linkers {(G4S)2} between gp120 and
each C3d repeat.26,29,30 A second gp120R2 gene was synthesized to encode for the gp120
molecule (amino acids 1–526) using codons for enhanced expression in mammalian cells
(GeneArt, Regensburg, Germany). In addition, the synthetic gp120R2 gene was cloned in frame
with the mC3d3 gene.14,40 Lastly, oligonucleotides were constructed to introduce into the
gp120ADA or gp12089.6 genes a proline/methionine (Pro–Met) at amino acids 313/314 in the
V3 loop by polymerase chain reaction (PCR)-based mutagenesis (Fig. 1B). The same mutations
were introduced into the gp120ADA–C3d3–DNA and gp12089.6–C3d3–DNA.
The plasmids were amplified in Escherichia coli strain DH5?, purified using endotoxin-free,
anion-exchange resin columns (Qiagen, Valencia, CA) and stored at –20°C in dH2O. Plasmids
were verified by appropriate restriction enzyme digestion and gel electrophoresis. Purity of
DNA preparations was determined by optical density reading at 260 and 280 nm and, therefore,
each DNA vaccine inoculation contained >50 fg/?g of endotoxin per DNA inoculation.
Transfections and expression analysis
The human embryonic kidney cell line 293T (5 × 105 cells/transfection) was transfected with
1 ?g of DNA using 12% lipofectamine according to the manufacturer's guidelines (Life
Technologies, Grand Island, NY). Supernatants were collected and stored at –20°C. Cell lysates
were collected in 300 ?l of 1% Triton-X buffer and stored at –20°C. Quantitative antigen
capture ELISAs were conducted as previously described.24,26,29 Alternatively, monoclonal
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antibodies (IgG1b12, F105, 2F5, 17b, 48d)25,41–43 were used to detect the fusion proteins in
ELISA. All DNA expressing gp120 from wild-type sequences produced equal amounts of
protein (ᙺ1 ?g/?l), which was three to four times higher than the amount of protein expressed
from gp120–mC3d3–DNA. DNA expressing the same molecules from codon-optimized gene
sequences elicited ᙺ10 times higher amounts of protein (data not shown). Similar results were
observed for wild-type and codon-optimized Env gene sequences from isolates HIV-1ADA and
HIV-189.6. The introduction of the Pro–Met mutation at amino acids 313/314 did not affect
protein expression (data not shown).
Iodination and binding of sgp120 to cell surface receptors
The gp120 or gp120–mC3d3 molecules were labeled using Iodobead (Pierce, Rockford, IL)
iodination of 10 ?g of protein for 5 min in a 150 ?l volume of phosphate-buffered saline (PBS),
using 250 ?Ci of Na125I preincubated for 5 min with one Iodobead.44 125I incorporation rates
of greater than approximately 50% resulted in oxidative destruction of protein that was no
longer capable of binding any receptor. Radiolabeled proteins were purified from free Na125I
by separation through a 0.3-ml Dowex column prepared in a 1-ml syringe and preequilibrated
in a mixture containing 50 mM HEPES (pH 7.4), 5 mM MgCl2, 1 mM CaCl2, 1% bovine serum
albumin (BSA), and 150 mM NaCl. Protein fractions were eluted in the void volume of the
column, and the fractions containing peaks of labeled protein were combined. The integrity of
gp120 after radiolabeling was verified by sodium dodecyl sulfate–polyacrylamide gel
electrophoresis (SDS–PAGE) and autoradiography.
Env binding assays were performed by resuspending HOS CCR5+ or HOS CXCR4+ cells in
75 ?l of HEPES binding buffer [50 mM HEPES (pH 7.4), 5 mM MgCl2, 1 mM CaCl2, 5%
BSA, 0.1% NaN3]. Labeled proteins were added to cells in 25 ?l of binding buffer for a total
volume of 100 ?l. Cells were incubated at room temperature (RT) for 1 hr. Unbound
radioactivity was removed by filtering cells through 25-mm filters (Whatman, Clifton, NJ)
presoaked in 0.2% polyethyleneimine (Sigma, St. Louis, MO) and thoroughly washed. Filters
were counted in a gamma counter and results are expressed as counts per minute. For
competition experiments, radiolabeled gp120 and gp120–mC3d3 proteins were incubated with
monoclonal antibody 17b (1 ?g/?l) for 1 hr at 37°C. Cells were pelleted and washed with PBS
and then analyzed in a gamma counter.
Animals and DNA immunizations
Six- to 8-week-old BALB/c mice (Harlan Sprague Dawley, Indianapolis, IN) were vaccinated
intradermally using particle bombardment (gene gun) inoculations. Gene gun immunizations
were performed on shaved abdominal skin of anethesized mice as described previously.26,
34,45,46 Mice were immunized with two gene gun doses containing 1 ?g of DNA per 0.5 mg
of approximately 1 ?m gold beads (Bio-Rad, Hercules, CA) at a helium pressure setting of 400
psi.
Immunological assays
An endpoint ELISA was performed to assess the titers of anti-Env IgG in immune serum28
using matched, recombinant HIV-1 gp120 protein to coat plates purified as previously
described.24 Mouse sera from vaccinated mice were allowed to bind and subsequently were
detected by antimouse IgG conjugated to horseradish peroxidase (Southern Biotechnology,
Birmingham, AL). Endpoint titers were considered positive that were 2-fold higher than
background. Similar ELISAs were performed to determine the isotype of IgG (IgG1 or
IgG2a) or other immunoglobulin classes, IgM, IgE, and IgA, elicited by vaccination. All assays
were performed in triplicate.
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Avidity ELISAs were performed similarly to serum antibody determination ELISAs up to the
addition of samples and standards.26,28–30,33,34,47–52 Samples were diluted to give similar
concentrations of specific IgG by OD. Plates were washed three times with 0.05% PBS-Tween
20. Different concentrations of the chaotropic agent sodium thiocyanate (NaSCN) in PBS were
then added (0, 1, 1.5, 2, 2.5, and 3 M NaSCN). Plates were allowed to stand at room temperature
for 15 min and then washed six times with PBS-Tween 20. Subsequent steps were performed
similarly to the serum antibody determination ELISA. Percent of initial IgG was calculated as
a percent of the initial OD. All assays were done in triplicate.
Neutralization of virus infection
Pseudotyped viruses were prepared by transfection of 293T cells with pNL4-3.luc.E-R and
envelope-expressing plasmids, as previously described.53,54 Infectivity and neutralization
assays were carried out using HOS CD4+ CCR5+, HOS CD4+ CXCR4+, HOS CCR5+, or HOS
CXCR4+ cells.12,40,53–55 Infectivity was determined on the basis of luminescence measured
3 days after infection. As previously described, neutralization assays were performed by
preincubation of serial serum with pseudotyped viruses [ADA, 89.6, R2 (clade B), 92UG029
(clade A), or 92BR025 (clade C)] prior to cell infection.12,53,54 The average dilution of 50%
of the mean luminescence from three independent experiments was determined for each serum
sample for each pseudotyped virus. In addition, the nonspecific neutralizing titer from naive,
age-matched mice at each dilution was subtracted from each value.
Statistics
For statistical analysis, a Student's t test was employed. The difference between gp120 fused
to multiple copies of murine C3d and gp120 alone or fused to murine C3d was determined.
Differences were considered statistically significant when p < 0.05.
RESULTS
Binding of monoclonal antibodies to envelope
The gp120R2 was more easily recognized by the monoclonal antibodies 17b and 48d,43,57–
61 which recognize CD4-induced epitopes, compared to gp120ADA or gp12089.6 (Table 1).
Similar results were observed with gp120ADA(Pro–Met) and gp12089.6(Pro–Met). The addition of
mC3d3 did not inhibit the binding by any of the monoclonal antibodies (Table 1). All the gp120
molecules were recognized by the monoclonal antibodies F105 and 1b12 and the monoclonal
antibody 2F5, which maps to a linear sequence in gp41, did not recognize any of the expressed
gp120 envelopes. The addition of sCD4 to gp120ADA or gp12089.6 enhanced the binding of
17b and 48d (Table 1), however, sCD4 did not increase the binding of these antibodies to
gp120R2. Therefore, CD4-induced epitopes are exposed on the gp120R2 molecule, as well as
gp120, incorporating the Pro–Met mutation, which are recognized by antibodies that usually
bind only following exposure to hCD4.
Binding of gp120 to cell surface receptors
Radiolabeled gp120R2 directly bound to cells expressing hCCR5, but not to cells expressing
hCXCR4 (Table 2). The addition of mC3d3 to the 3? end of the fusion protein did not affect
the binding of gp120R2 to the cell surface chemokine receptors. gp120ADA or gp12089.6 did
not bind to coreceptor expressing cells, however, both molecules did bind to cells expressing
hCD4 (data not shown). However, envelopes with the Pro–Met mutation efficiently bound to
appropriate coreceptor expressing cells. The addition of anti-hCCR5 antibodies (Table 2) or
nonradioactive gp120R2, gp120ADA(Pro–Met), or gp12089.6(Pro–Met) (data not shown)
significantly (p > 0.05) competed with the radiolabeled proteins.
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Antibody response to gp120-mC3d3 DNA immunizations
As previously reported,24,26,29,30,33 mice vaccinated with DNA plasmid (2 ?g) expressing
the gp120R2–mC3d3 from wild-type sequences (day 1 and then boosted at weeks 4 and 8) raised
detectable titers of anti-Env antibody (1:6200 at week 8) (Fig. 2A). Few, if any, anti-EnvR2
antibodies were detected in mice vaccinated with gp120R2–DNA following three inoculations.
In contrast, mice vaccinated with DNA expressing gp120R2 or gp120R2–mC3d3 from codon-
optimized sequences (2 ?g) had detectable titers (both IgG1 and IgG2a) after the first
immunization, which were boosted following additional inoculations (Fig. 2A). Mice
vaccinated with gp120R2–mC3d3–DNA using codon-optimized sequences had an average
peak titer that was greater than 1 log higher (>1:000,000 at week 8) than mice vaccinated with
gp120R2–mC3d3–DNA using wild-type sequences (<1:10,000 at week 8). In addition, mice
vaccinated with gp120R2–DNA using codon-optimized sequences elicited similar, or in some
cases higher, titers than C3d-conjugated forms (Fig. 2A). Similar results were observed in
collected sera from mice vaccinated with vaccines using the gp120ADA, gp120ADA(Pro–Met),
gp12089.6, or gp12089.6(Pro–Met) (Fig. 2B and C). The introduction of the Pro–Met mutation
into the gp120ADA or gp12089.6 did not appear to affect the titers of IgG elicited in vaccinated
mice, regardless of whether the proteins were expressed from wild-type or codon-optimized
sequences. Therefore, at this dose of inoculum, the C3d enhancement effect was masked when
the fused protein was expressed from DNA using codon-optimized gene sequences.
Interestingly, mice vaccinated with DNA expressing non-C3d versions of each gp120 molecule
had detectable titers of IgG1, but little or no titers of IgG2a at week 10 (data not shown).
However, mice vaccinated with DNA expressing C3d-conjugated gp120 molecules elicited
similar titers of IgG1 and IgG2a. The use of codon-optimized gene sequences did not alter the
ratio between the two immunoglobulin classes, even though the overall titer was approximately
1 log higher.
The avidity of the antibody generated with DNA expressing gp120–mC3d3 was consistently
higher than antisera from gp120–DNA vaccinated mice. Antisera from mice vaccinated with
gp120–DNA had an ED50 of ᙺ0.5 M. However, mice vaccinated with DNA expressing gp120–
mC3d3 had an ED50 of ᙺ1.5 M (week 10). Similar results were observed from mice vaccinated
with DNA expressing gp120ADA(Pro–Met) or gp12089.6(Pro–Met). These results indicate that the
Pro–Met mutation did not affect the maturation of the anti-Env antibody.
Envelopes with the Pro–Met mutation elicit cross-reactive neutralizing antibodies
Mice vaccinated with DNA expressing gp120 using wild-type gene sequences were unable to
neutralize viral infection (week 10) due to the lack of anti-Env antibodies (Fig. 2), whereas,
the addition of C3d raised antibodies capable of neutralizing homologous infection (1:16
dilution) (Table 3). However, DNA plasmid expressing neither gp120ADA–mC3d3, nor
gp12089.6-mC3d3 was able to elicit antibodies that significantly prevented heterologous viral
infection.
Mice vaccinated with DNA expressing gp120R2 from codon-optimized gene sequences elicited
high titers of neutralizing antibodies against HIV-1R2 (1:80 dilution). The addition of C3d to
gp120 raised the neutralizing antibodies (1:256 dilution) that neutralized homologous virus
infection. Furthermore, conjugation of C3d to gp120R2 broadens the neutralizing capacity of
the antisera, preventing virus infection by the heterologous viruses (Table 3). Mice vaccinated
with DNA expressing gp120ADA ± mC3d3 from codon-optimized gene sequences did not
broaden the number of viruses neutralized compared to non-C3d-conjugated gp120ADA. In
addition, mice vaccinated with gp120ADA(Pro–Met)–mC3d3–DNA using codon-optimized
genes neutralized both homologous and heterologous viruses (Table 3). Overall, codon
optimization or C3d fusion enhanced the titer of neutralizing antibody. However, the induction
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of the highest titers of cross-reactive, neutralizing antibodies was elicited by C3d coupled to
gp120R2 or to a gp120 incorporating the unique V3 loop mutations found in EnvR2.
DISCUSSION
In this study, DNA plasmids expressing the envelope from the HIV-1R2 (isolated from donor
HNS2) were used to elicit high titer neutralizing antibodies in vaccinated mice (Table 3). Serum
collected from donor HNS2, a long-term nonprogressor, had antibodies that neutralized
primary isolates from a broad range of clades.15 Interestingly, when the EnvR2 is pseudotyped
onto a virion, the virus is easily neutralized by anti-HIV sera.14 Therefore, we hypothesized
that the gp120 subunit of EnvR2 would elicit cross-reactive neutralizing antibodies expressed
from a DNA plasmid following vaccination. To enhance titers of anti-Env antibodies by DNA
plasmids expressing gp120R2, two strategies were employed: (1) codon optimization of the
gp120R2 gene sequences62,63 and (2) the use of C3d conjugated to gp120R2.24,26,29,30,64
Each strategy raised high titer anti-Env antibodies that neutralized homologous HIV-1R2 viral
infection, however, the combination of both codon optimization and C3d to gp120R2 elicited
the broadest neutralizing antibody responses (Table 3).
The EnvR2 has a rare mutation in the proximal limb of variable region 3 (V3), amino acids
313–314, Pro–Met.12,54 The neutralization sensitivity of this envelope has been mapped to
this unique region of V3.14 Recently, Zhang et al.14 demonstrated that the EnvR2 was highly
sensitive to neutralization by the monoclonal antibody 19b, which is directed against
conformation-sensitive epitopes at the crown of the V3 loop. The binding of specific
monoclonal antibodies that recognize CD4-induced epitopes is also dependent on this region
(Table 1). A unique double turn is located at the apex of the V3 loop (GPGRAF) that is highly
conserved across clade B isolates.65 A proline residue immediately 5? to the V3 loop apex
could significantly alter the structure of the V3 loop, resulting in exposure of the coreceptor
binding site.66 Unlike most HIV-1 envelopes, the gp120R2 specifically bound to cells
expressing hCCR5 (Table 2), indicating that the conformation of this envelope allows for
coreceptor binding without the necessity of prior hCD4 interaction. The exposure of the
coreceptor binding site in EnvR2 could explain the enhanced sensitivity of this envelope to
neutralization.
The EnvR2, or the unique sequences located in EnvR2, could be an attractive immunogen for
inducing neutralizing antibodies in humans following vaccination.67,68 Recently, Dong et
al.15 demonstrated that neutralizing antibodies can be induced using a VEE replicon system
expressing the EnvR2. Therefore, in this study, the unique sequence at the crown of the V3
loop in EnvR2 was introduced into two envelopes that do not normally elicit high titer
neutralizing antibodies. Even though there are differences in the V3 loop sequences of
EnvR2 and EnvADA (four amino acids) or Env89.6 (eight amino acids), the apex sequence is
conserved in all three envelopes (Fig. 1). Mice vaccinated with each of these mutated envelopes
did not dramatically enhance the neutralizing titers to homologous virus challenge regardless
of whether the genes were expressed from wild-type or codon-optimized sequences (Table 3).
However, the addition of C3d to these envelopes not only enhanced the anti-Env titer, but also
broadened the number of viruses neutralized by collected sera (Table 3).
This study confirms that C3d can act as a molecular adjuvant to enhance antibody responses
to the conjugated antigen. However, the mechanism(s) of action of C3d are still unclear.
Recently, we demonstrated that unexpectedly, C3d can function as an effective adjuvant in the
absence of CD21/35 expression.38 C3d has been shown to bind to CD21 (CR2) resulting in
the coligation of CD19 to CD21, which, in turn, stimulates a signaling cascade that leads to
the proliferation of B lymphocytes.32 However, the only direct evidence supporting this
conclusion was that pretreatment of mice with an antibody against CD21 suppressed the effect
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elicited by C3d. Although anti-CD21 monoclonal treatment is known to inhibit humoral
immune responses to a variety of antigens,69–71 anti-CD21 monoclonal antibody treatment
may have effects on B cell function beyond blocking C3d binding.72 Therefore, C3d may
enhance immune responses, including cellular responses,24,64 by multiple mechanisms. C3d
may possibly enhance the uptake and processing of conjugated antigens by B cells, which
results in enhanced antigen presentation. Also, the process by which C3d enhances neutralizing
antibodies remains unclear, however, this enhancement is dependent on the neutralization
potential of the conjugated immunogen. The gp120 proteins with a modified V3 loop used in
this study and trimeric forms of Env (gp140)24 both elicited neutralizing antibodies that were
enhanced by conjugation to C3d.
Despite the delayed appearance of neutralizing antibody in infected patients47 (6–8 months to
achieve affinity maturation), this component of the immune response appears important in
controlling infection. Immunogens that elicit high titer anti-envelope antibodies are one
component of a vaccine needed for a multifaceted immune response against HIV-1. Even
though DNA-expressing gp120 molecules conjugated to C3d or expressed using codon-
optimized gene sequences elicited higher titer anti-Env antibodies, only mice vaccinated with
EnvR2 had cross-reactive neutralizing antibodies (Table 3). Interestingly, the introduction of
the unique Pro–Met mutation into a prototypic R5 envelope (ADA) or a prototypic dual tropic
envelope (89.6) enhanced the neutralizing capacity of these proteins. Mice vaccinated with
DNA using codon-optimized gp120ADA(Pro–Met) genes fused to mC3d3 elicited 4- to 8-fold
high titers of neutralizing antibodies than nonmutated envelopes (Table 3). Therefore, the Pro–
Met mutation in EnvR2 is most likely responsible for the constitutively exposed coreceptor
binding site on the molecule. In addition, envelope immunogens incorporating the EnvR2
sequence induced broadly cross-reactive neutralizing antibodies following immunization.
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FIG. 1.
(A) The first schematic represents the secreted gp120 form of the envelope used as a vaccine
insert. The second schematic represents the sgp120–C3d3 construct used as a vaccine insert.
The third schematic represents the C3d3 construct used as a vaccine insert. Linkers composed
of two repeats of four glycines and a serine {(G4S)2} were fused at the junctures between gp120
and C3d and between each C3d repeat. (B) V3 loop sequence representing R2, ADA, and 89.6.
The superscript Pro–Met represents proline and methionine mutation introduced into
gp120ADA and gp12089.6. Undelined amino acids indicate additional amino acids that differed
with the R2 sequence.
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FIG. 2.
Anti-Env IgG raised by DNAs expressing gp120 in gene gun vaccinated mice. Mice were
primed with DNA at day 0 and boosted at weeks 4 and 8. Sera were obtained from mice every
2 weeks. Serum collected at the indicated times from each mouse was assayed for specific IgG
levels by ELISA. Plates (96-well) were coated with recombinant gp120R2 protein. Data are
represented as the average of 10 mice. Preimmune serum from mice had no detectable specific
IgG. Endpoint dilution titers were conducted by diluting the sera until OD values reached
background. (A) Time course of DNA expressing R2 immunogens. (B) Range of endpoint
dilution titer from collected serum (week 10) from mice vaccinated with DNA expressing R2
immunogens. (C) Time course of DNA expressing 89.6 immunogens. (D) Range of endpoint
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dilution titer from collected serum (week 10) from mice vaccinated with DNA expressing 89.6
immunogens. (E) Time course of DNA expressing DNA immunogens. (F) Range of endpoint
dilution titer from collected serum (week 10) from mice vaccinated with DNA-expressing ADA
immunogens.
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Table 1.
Binding of Monoclonal Antibodies to gp120 ± mC3d3
Monoclonal antibody
Samples F105 1b12 2F5 48d 17b
R2
wt gp120 25,000a 25,000 <10 50,000 25,000
wt gp120–mC3d3 25,000 25,000 <10 12,500 12,500
wt gp120 + sCD4 50,000 12,500 <10 50,000 25,000
wt gp120–mC3d3 + sCD4 25,000 50,000 <10 25,000 50,000
ADA
wt gp120 25,000 25,000 <10 1,600 800
wt gp120–mC3d3 25,000 25,000 <10 400 400
wt gp120 + sCD4 50,000 25,000 <10 25,000 25,000
wt gp120–mC3d3 + sCD4 50,000 50,000 <10 25,000 25,000
ADA (PM)
wt gp120 50,000 25,000 <10 25,000 25,000
wt gp120–mC3d3 25,000 25,000 <10 12,500 25,000
wt gp120 + sCD4 25,000 25,000 <10 25,000 25,000
wt gp120–mC3d3 + sCD4 50,000 25,000 <10 25,000 25,000
89.6
wt gp120 25,000 25,000 <10 3,200 400
wt gp120–mC3d3 25,000 25,000 <10 400 400
wt gp120 + sCD4 50,000 25,000 <10 25,000 50,000
wt gp120–mC3d3 + sCD4 50,000 25,000 <10 50,000 50,000
89.6 (PM)
wt gp120 25,000 25,000 <10 25,000 25,000
wt gp120–mC3d3 25,000 25,000 <10 25,000 25,000
wt gp120 + sCD4 25,000 25,000 <10 25,000 25,000
wt gp120–mC3d3 + sCD4 25,000 25,000 <10 50,000 50,000
a
Value represents the inverse of the endpoint dilution titer
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Table 2.
Binding of 125I Radiolabeled HIV-1 Envelope to HOS Cells Expressing the Coreceptors hCCR5 or hCXCR4
Coreceptor expressing cellsa
Samples hCCR5 hCXCR4 Anti-hCCR5b
R2
wt gp120 22,501 ± 3,510c 355 ± 127 174 ± 57
wt gp120–mC3d3 22,013 ± 1,568 241 ± 205 256 ± 32
co gp120 17,129 ± 3,629 267 ± 130 50 ± 29
co gp120–mC3d3 18,219 ± 578 97 ± 75 117 ± 92
ADA
wt gp120 323 ± 510 200 ± 110 152 ± 71
wt gp120–mC3d3 287 ± 168 41 ± 23 129 ± 86
co gp120 297 ± 62 67 ± 130 96 ± 92
co gp120–mC3d3 253 ± 57 97 ± 75 117 ± 41
ADA (PM)
wt gp120 19,445 ± 2,520 65 ± 12 74 ± 17
wt gp120–mC3d3 15,553 ± 1,678 79 ± 135 67 ± 44
co gp120 23,894 ± 2,004 234 ± 108 95 ± 20
co gp120–mC3d3 16,283 ± 1,741 197 ± 107 150 ± 37
89.6
wt gp120 384 ± 139 105 ± 62 113 ± 30
wt gp120–mC3d3 446 ± 43 333 ± 143 129 ± 43
89.6 (PM)
wt gp120 21,490 ± 3,102 17,265 ± 1,009 372 ± 170
wt gp120–mC3d3 29,835 ± 4,688 9,312 ± 4,510 174 ± 74
a
HOS cells expressed either hCCR5 or hCXCR4, but not hCD4
b
10 mg/ml of 17b mixed with protein prior to cell incubation
c
Value represents the inverse of the endpoint dilution titer. All values represent the average counts per minute of three independent experiments ± SEM
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Table 3.
Elicitation of Neutralizing Antibodies by DNA Vaccines
Viral isolatea
Samples R2 ADA 89.6 A C
R2
wt gp120 <10b <10 <10 <10 <10
wt gp120–mC3d3 16 <10 <10 <10 <10
co gp120 80 <10 <10 <10 <10
co gp120–mC3d3 256 32 56 24 48
ADA
wt gp120 <10 <10 <10 <10 <10
wt gp120–mC3d3 <10 32 <10 <10 <10
co gp120 <10 <10 <10 <10 <10
co gp120–mC3d3 20 72 <10 <10 <10
ADA (PM)
wt gp120 <10 <10 <10 <10 <10
wt gp120–mC3d3 <10 24 <10 <10 <10
co gp120 <10 <10 <10 <10 <10
co gp120–mC3d3 40 96 20 24 20
89.6
wt gp120 <10 <10 <10 <10 <10
wt gp120–mC3d3 <10 <10 40 <10 <10
89.6 (PM)
wt gp120 <10 <10 <10 <10 <10
wt gp120–mC3d3 <10 <10 20 <10 <10
a
Clade B, R2, ADA, 89.6; clade A, 92UG029; clade C, 92BR025
b
Value represents the inverse of the endpoint dilution titer, n = 10. Clade 50% neutralization of viral infection. The average of three independent experiments
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